May 8, 2023 7:00 am EDT Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025
Apr 4, 2023 8:01 am EDT Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND
Mar 13, 2023 8:00 am EDT Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange
Mar 8, 2023 9:00 am EST Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference
Feb 7, 2023 9:00 am EST Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023
Jan 25, 2023 9:00 am EST Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule